With operations across 50 countries, MagicLab is pairing new robot systems with a platform strategy aimed at wider commercial adoption
Updated
May 1, 2026 2:16 PM
.jpg)
A standing yellow robotic arm. PHOTO: UNSPLASH
MagicLab Robotics is a Chinese startup that describes itself as an embodied AI company. At an event in Silicon Valley this week, it outlined its global ambitions and introduced new products designed for real-world use. The company said its international business now spans more than 50 countries and regions, with overseas markets accounting for 60% of total sales in 2025. That gives some indication of how quickly Chinese robotics firms are expanding beyond their home market.
At the centre of the announcement was MagicLab’s latest product line-up. It included Magic-Mix, described as a foundational world model for robots, the H01 dexterous robotic hand and its humanoid robot, MagicBot X1. In practical terms, the company is trying to build robots that can better understand their surroundings and perform physical tasks with greater precision. That is the core idea behind embodied AI, where intelligence is combined with movement and interaction in the real world rather than limited to software alone.
MagicLab says it develops both hardware and software internally. Its product range includes humanoid robots and four-legged machines, with systems designed for factories, commercial services and home use. The company also outlined where it sees demand emerging. It listed sectors such as healthcare, manufacturing, logistics, security, public safety, education and household assistance.
That wide spread of target markets reflects a broader challenge in robotics. Building capable machines is only one part of the equation. The harder task is finding enough practical uses where customers are willing to pay for them.
MagicLab also used the summit to set out a long-term commercial goal. It projected a path toward US$14 billion in annual revenue by 2036 through wider adoption of embodied AI systems. It also announced what it calls the “Co-Create 1000 Initiative”, a plan to work with external developers and partner companies.
As part of that effort, the startup said it plans to invest US$1 billion over the next five years to build a developer ecosystem that would allow third parties to create new applications for its robots. The strategy mirrors what happened in smartphones and cloud software, where ecosystems often mattered as much as the original hardware. If robotics follows a similar path, companies that attract developers could gain an advantage over those selling machines alone.
For now, MagicLab’s announcement is less about immediate breakthroughs and more about positioning. The company is presenting itself not simply as a robot maker, but as a platform business seeking a role in the next phase of intelligent machines.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.